Donovan Quill, President and CEO, Optime Care, featured in June issue of Pharmaceutical Manufacturing.
It is estimated that close to 95% of the identified 7,000+ rare diseases have no FDA-approved treatments. This equates to a huge unmet need in the market for orphan drugs.
More players in the rare disease space means more opportunities to bring cures to this patient population at need. Large pharma companies entering the space could be seen as a big positive as they have the money to invest and to bring products to market.
This article explores the role of pharma in the rare disease market space, as well as the organizations and companies willing to collaborate, highlighting Optime Care’s patient-first approach to addressing the needs of each individual patient.
